Boston Scientific Settles 14 Stent Patent Suits With J&J For $716 Million
This article was originally published in The Gray Sheet
Executive Summary
Long-time stent rivals Boston Scientific and Johnson & Johnson signed a partial patent détente Sept. 29, but the companies are not finished battling over intellectual property for the profitable devices
You may also be interested in...
J&J/Cordis v. Boston Scientific
Johnson & Johnson's Cordis unit plans to appeal a Jan. 20 ruling in Delaware federal court that found four of its drug-eluting stent patents to be invalid. The so-called Wright/Falotico patents relate to drug and polymer coatings for stents and are at issue in a 2007 suit brought by J&J/Cordis claiming infringement by Boston Scientific's Promus everolimus-eluting stent system. J&J notes that the ruling "is not expected to have any effect on Cordis' other litigation against the Promus product based on its Morris, Llanos and Fischell patent families." Last fall, Boston Scientific settled 14 other stent patent suits with J&J by paying $716 million. "We continue to attempt to resolve remaining outstanding matters with J&J," said Boston Scientific CEO Ray Elliott on Jan. 20 (1"The Gray Sheet" Oct. 5, 2009)
J&J/Cordis v. Boston Scientific
Johnson & Johnson's Cordis unit plans to appeal a Jan. 20 ruling in Delaware federal court that found four of its drug-eluting stent patents to be invalid. The so-called Wright/Falotico patents relate to drug and polymer coatings for stents and are at issue in a 2007 suit brought by J&J/Cordis claiming infringement by Boston Scientific's Promus everolimus-eluting stent system. J&J notes that the ruling "is not expected to have any effect on Cordis' other litigation against the Promus product based on its Morris, Llanos and Fischell patent families." Last fall, Boston Scientific settled 14 other stent patent suits with J&J by paying $716 million. "We continue to attempt to resolve remaining outstanding matters with J&J," said Boston Scientific CEO Ray Elliott on Jan. 20 (1"The Gray Sheet" Oct. 5, 2009)
Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.
Medtronic will pay Abbott Laboratories $400 million to resolve a costly series of global stent patent battles that have dragged on since the '90s and in some cases limited the companies' ability to commercialize in certain markets